Silver Michelle I, Rositch Anne F, Burke Anne E, Chang Katie, Viscidi Raphael, Gravitt Patti E
Departments of Epidemiology, Gynecology and Obstetrics, and Pediatrics and the Center for Immunization Research, Johns Hopkins School of Public Health, Baltimore, Maryland; and the Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.
Obstet Gynecol. 2015 Feb;125(2):317-329. doi: 10.1097/AOG.0000000000000638.
To explore attitudes toward new cervical cancer screening options and understand factors associated with those beliefs among women in routine gynecologic care.
We used an interviewer-administered survey of 551 women aged 36-62 years enrolled in the HPV in Perimenopause Study. Poisson regression with robust error variance was used to estimate prevalence ratios and 95% confidence intervals (CIs) to compare women's preferences for cervical cancer screening methods and frequency.
A majority of women (55.6%, 95% CI 51.4-59.8%) were aware that screening recommendations had changed, yet 74.1% (95% CI 70.3-77.7%) still believed women should be screened annually. If recommended by their doctor, 68.4% (95% CI 64.4-72.2%) were willing to extend screening to every 3 years, but only 25.2% (95% CI 21.9-29.2%) would extend screening to 5 years. Most women (60.7%, 95% CI 56.5-65.7%) expressed a strong preference for Pap testing, and 41.4% (95% CI 37.4-45.6%) expressed at least moderate concern over having a human papillomavirus (HPV) test without a Pap test. A desire for more frequent care, higher degree of worry and perceived risk, and abnormal screening history were all associated with reduced willingness to accept HPV testing and longer screening intervals.
A majority of routinely screened women indicated a willingness to adopt a cervical cancer screening strategy of cytology alone or Pap-HPV cotesting every 3 years if recommended by their physician. However, they remain concerned about HPV testing and extension of screening intervals to once every 5 years. Our results suggest continued reticence to accepting newer HPV-based screening algorithms among routinely screened women older than age 35 years.
探讨常规妇科护理中女性对新的宫颈癌筛查方案的态度,并了解与这些观念相关的因素。
我们对参与围绝经期人乳头瘤病毒(HPV)研究的551名36至62岁女性进行了访谈式调查。采用具有稳健误差方差的泊松回归来估计患病率比和95%置信区间(CI),以比较女性对宫颈癌筛查方法和频率的偏好。
大多数女性(55.6%,95%CI 51.4 - 59.8%)知晓筛查建议已发生变化,但仍有74.1%(95%CI 70.3 - 77.7%)认为女性应每年进行筛查。如果医生建议,68.4%(95%CI 64.4 - 72.2%)的女性愿意将筛查延长至每3年一次,但只有25.2%(95%CI 21.9 - 29.2%)会将筛查延长至每5年一次。大多数女性(60.7%,95%CI 56.5 - 65.7%)表示强烈倾向于巴氏试验,41.4%(95%CI 37.4 - 45.6%)表示至少对不进行巴氏试验而进行人乳头瘤病毒(HPV)检测存在中度担忧。更频繁护理的需求、更高程度的担忧和感知风险以及异常的筛查史均与接受HPV检测的意愿降低和更长的筛查间隔相关。
大多数接受常规筛查的女性表示,如果医生建议,她们愿意采用单独细胞学检查或每3年进行一次巴氏 - HPV联合检测的宫颈癌筛查策略。然而,她们仍对HPV检测以及将筛查间隔延长至每5年一次感到担忧。我们的结果表明,35岁以上接受常规筛查的女性在接受基于HPV的新筛查算法方面仍存在顾虑。